A near-infrared light-responsive extracellular vesicle as a “Trojan horse” for tumor deep penetration and imaging-guided therapy

Xu, Zeng; Huang, Huabei; Xiong, Xiang‐Yuan; Wei, Xiaoguang; Guo, Xing; Zhao, Jingya; Zhou, Shaobing

doi:10.1016/j.biomaterials.2020.120647

Cited by 51 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVs can be stored for long durations, with reduced loss of function compared with cells applied in therapeutic strategies (25). Moreover, the cargo encapsulated by EVs or NVs has showed more stable functions than free cargo (26)(27)(28), suggesting the potential applications of EVs or NVs in drug delivery (29). Previous studies have shown that mechanical extrusion is a feasible method for producing NVs (30,31); in addition, NVs derived from M1 macrophages contain specific RNAs (5).…”

Section: Discussionmentioning

confidence: 99%

M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis

Yuan

Xue

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundEndometriosis is a common nonmalignant gynecological disorder that affects 10–15% women of reproductive age and causes several symptoms that result in decreased quality of life and a huge social burden. In recent decades, extracellular vesicles (EVs) have gained attention as a potential therapeutic tool; however, the therapeutic effects of EVs against endometriosis have not been reported. Accordingly, in this study, we investigated the feasibility of nanovesicles (NVs) derived from M1 macrophages (M1NVs) in treating endometriosis.MethodsM1NVs were prepared by serial extrusion. Co-culture assays were performed to investigate changes in tube formation and migration/invasion of eutopic endometrial stroma cells (ESCs) obtained from patients with endometriosis (EM-ESCs). A mouse model of endometriosis was established, and mice were treated with phosphate-buffered saline, M0NVs, or M1NVs to evaluate the efficacy and safety of M1NV for treating endometriosis.ResultsM1NVs directly or indirectly inhibited the migration and invasion of EM-ESCs and reduced tube formation. In the mouse model, M1NVs suppressed the development of endometriosis through reprogramming of M2 macrophages, without causing damage to the organs.ConclusionsM1NVs inhibit the development of endometriosis directly, or through repolarizing macrophages from M2 to M1 phenotype. Hence, administration of M1NVs may represent a novel method for the treatment of endometriosis.

show abstract

Section: Discussionmentioning

confidence: 99%

M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis

Yuan

Xue

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Fifth, many NPs were trapped by the mononuclear phagocyte system in livers, how to make the NPs evade immune surveillance and penetrate into the tumor tissue is pivotal to maximize the therapeutic potency, but it is challenging. 53 In conclusion, we established a new multifunctional nanoplatform designated Fe 3 O 4 -PEG-Cy7-EMO providing FI/MRI imaging and therapeutic treatment for PC cells. In vivo FI and MRI experiments showed the passive targeting and contrast ability of the nanoprobes in tumor-bearing mouse models.…”

mentioning

confidence: 91%

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

Ren¹,

Song²,

Tian³

et al. 2021

IJN

View full text Add to dashboard Cite

“…synthesized 4.2 nm Ag 2 S QDs that could be co‐loaded with DOX into macrophage cell‐secreted microvesicles of size 489 nm (MVs@QDs&DOX) by electroporation. [ 199 ] Following the accumulation of the complex in tumors enabled by inherent tumor‐targeting activity of the MVs, the MVs were be disintegrated using the Ag 2 S QD‐induced NIR photothermal effect to release the anti‐cancer QDs and DOX, enabling effective tumor killing and therapeutic penetration to a depth of ≈9 mm; the ultra‐small QDs could subsequently be excreted through the renal route to avoid potential toxicity. Trojan‐horse nanoparticles can also be designed to demonstrate multifunctional stimuli responses, supporting both therapeutic delivery and diagnostic modalities.…”

Section: Size‐switching Strategiesmentioning

confidence: 99%

Design of Smart Size‐, Surface‐, and Shape‐Switching Nanoparticles to Improve Therapeutic Efficacy

Montague

Pollinzi

et al. 2021

Small

View full text Add to dashboard Cite

Multiple biological barriers must be considered in the design of nanomedicines, including prolonged blood circulation, efficient accumulation at the target site, effective penetration into the target tissue, selective uptake of the nanoparticles into target cells, and successful endosomal escape. However, different particle sizes, surface chemistries, and sometimes shapes are required to achieve the desired transport properties at each step of the delivery process. In response, this review highlights recent developments in the design of switchable nanoparticles whose size, surface chemistry, shape, or a combination thereof can be altered as a function of time, a disease‐specific microenvironment, and/or via an externally applied stimulus to enable improved optimization of nanoparticle properties in each step of the delivery process. The practical use of such nanoparticles in chemotherapy, bioimaging, photothermal therapy, and other applications is also discussed.

show abstract

A near-infrared light-responsive extracellular vesicle as a “Trojan horse” for tumor deep penetration and imaging-guided therapy

Cited by 51 publications

References 43 publications

M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis

M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

Design of Smart Size‐, Surface‐, and Shape‐Switching Nanoparticles to Improve Therapeutic Efficacy

Contact Info

Product

Resources

About